Drug Sponsors

Allergan to restructure, cutting 1,500 employees

Monday, July 21, 2014 03:35 PM

As a result of a review of its operations and processes, Allergan will execute a restructuring it estimates will deliver annual pre-tax savings of approximately $475 million in calendar year 2015. Allergan will focus resources on the highest value opportunities, streamline its organizational structure, simplify processes and interfaces, optimize site footprints and enhancie strategic sourcing of goods and services.

More... »

WIRB Copernicus Group

AstraZeneca reveals designs for new U.K. global R&D center, corporate headquarters

Monday, July 21, 2014 03:03 PM

AstraZeneca revealed its proposed designs for its new global R&D center and corporate headquarters in Cambridge, U.K. The facility, which will be located on the Cambridge Biomedical Campus (CBC), includes the global center, an R&D enabling building and an energy center.

More... »

CRF Health eCOA webinar series

AbbVie to acquire Shire in $54.6 billion deal

Friday, July 18, 2014 10:24 AM

The boards of AbbVie and Shire have reached agreement on the terms of a recommended combination of Shire with AbbVie that values Shire at approximately $54.61 billion.

More... »

Pfizer to acquire InnoPharma

Thursday, July 17, 2014 12:48 PM

Pfizer has entered an agreement to acquire InnoPharma, a privately held pharmaceutical development company, for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.

More... »

Shire willing to discuss AbbVie’s 5th revised proposal

Monday, July 14, 2014 12:48 PM

Following discussions with AbbVie, Shirerequested and has received a further revised proposal from AbbVie on July 13 for a total offering of $53 billion.

More... »

Abbott to sell generics pharmaceuticals business to Mylan, form new entity

Monday, July 14, 2014 12:47 PM

Abbott will sell its non-U.S. developed markets branded generics pharmaceuticals business to Mylan for 105 million shares, or approximately 21%, on a fully diluted basis, of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business. The new entity will be a publicly traded company. This represents a value of approximately $5.3 billion based on Mylan's closing stock price on Friday.

More... »

Prostrakan to acquire Archimedes

Friday, July 11, 2014 11:26 AM

ProStrakan Group, a subsidiary of global specialty pharmaceutical company Kyowa Hakko Kirin (KHK), has entered into an agreement with Novo, a private limited liability company fully owned by the Novo Nordisk Foundation, to purchase the entire share capital of Archimedes Pharma for $394 million in cash.

More... »

Baxter acquires AesRx

Thursday, July 10, 2014 12:51 PM

Baxter International has acquired AesRx, a private U.S. biopharmaceutical company focused on orphan drug targets, including the development and commercialization of Aes-103, an investigational prophylactic treatment for sickle cell disease (SCD).

More... »

Salix Pharmaceuticals, Cosmo Technologies to merge

Thursday, July 10, 2014 12:33 PM

Salix Pharmaceuticals will merge with Cosmo Technologies, a subsidiary of Italy-based Cosmo Pharmaceuticals. Salix will become a wholly owned subsidiary of Irish-domiciled Cosmo Tech, which will change its name to Salix Pharmaceuticals.

More... »

Prescriptions in England up 60%, but costs up only 15% since 2003

Wednesday, July 9, 2014 12:10 PM

The number of prescription items dispensed in England has increased by 58.5% since 2003, according to a new Health and Social Care Information Center (HSCIC) analysis. Over 1.03 billion items were prescribed in 2013, compared to 649.7 million in 2003.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs